» Articles » PMID: 23531041

Photobiomodulation Preserves Behaviour and Midbrain Dopaminergic Cells from MPTP Toxicity: Evidence from Two Mouse Strains

Overview
Journal BMC Neurosci
Publisher Biomed Central
Specialty Neurology
Date 2013 Mar 28
PMID 23531041
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We have shown previously that near-infrared light (NIr) treatment or photobiomodulation neuroprotects dopaminergic cells in substantia nigra pars compacta (SNc) from degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Balb/c albino mice, a well-known model for Parkinson's disease. The present study explores whether NIr treatment offers neuroprotection to these cells in C57BL/6 pigmented mice. In addition, we examine whether NIr influences behavioural activity in both strains after MPTP treatment. We tested for various locomotive parameters in an open-field test, namely velocity, high mobility and immobility.

Results: Balb/c (albino) and C57BL/6 (pigmented) mice received injections of MPTP (total of 50 mg/kg) or saline and NIr treatments (or not) over 48 hours. After each injection and/or NIr treatment, the locomotor activity of the mice was tested. After six days survival, brains were processed for TH (tyrosine hydroxylase) immunochemistry and the number of TH⁺ cells in the substantia nigra pars compacta (SNc) was estimated using stereology. Results showed higher numbers of TH⁺ cells in the MPTP-NIr groups of both strains, compared to the MPTP groups, with the protection greater in the Balb/c mice (30% vs 20%). The behavioural tests revealed strain differences also. For Balb/c mice, the MPTP-NIr group showed greater preservation of locomotor activity than the MPTP group. Behavioural preservation was less evident in the C57BL/6 strain however, with little effect of NIr being recorded in the MPTP-treated cases of this strain. Finally, there were differences between the two strains in terms of NIr penetration across the skin and fur. Our measurements indicated that NIr penetration was considerably less in the pigmented C57BL/6, compared to the albino Balb/c mice.

Conclusions: In summary, our results revealed the neuroprotective benefits of NIr treatment after parkinsonian insult at both cellular and behavioural levels and suggest that Balb/c strain, due to greater penetration of NIr through skin and fur, provides a clearer model of protection than the C57BL/6 strain.

Citing Articles

Photobiomodulation for Neurodegenerative Diseases: A Scoping Review.

Shen Q, Guo H, Yan Y Int J Mol Sci. 2024; 25(3).

PMID: 38338901 PMC: 10855709. DOI: 10.3390/ijms25031625.


Transcranial photobiomodulation for brain diseases: review of animal and human studies including mechanisms and emerging trends.

Lin H, Li D, Zhu J, Liu S, Li J, Yu T Neurophotonics. 2024; 11(1):010601.

PMID: 38317779 PMC: 10840571. DOI: 10.1117/1.NPh.11.1.010601.


Parkinson's Disease and Photobiomodulation: Potential for Treatment.

Bicknell B, Liebert A, Herkes G J Pers Med. 2024; 14(1).

PMID: 38276234 PMC: 10819946. DOI: 10.3390/jpm14010112.


Remote photobiomodulation targeted at the abdomen or legs provides effective neuroprotection against parkinsonian MPTP insult.

Gordon L, Martin K, Torres N, Benabid A, Mitrofanis J, Stone J Eur J Neurosci. 2023; 57(9):1611-1624.

PMID: 36949610 PMC: 10947039. DOI: 10.1111/ejn.15973.


Transcranial near-infrared light in treatment of neurodegenerative diseases.

Nizamutdinov D, Ezeudu C, Wu E, Huang J, Yi S Front Pharmacol. 2022; 13:965788.

PMID: 36034819 PMC: 9400541. DOI: 10.3389/fphar.2022.965788.


References
1.
Ito T, Suzuki K, Uchida K, Nakayama H . Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B). Exp Toxicol Pathol. 2011; 65(1-2):153-8. DOI: 10.1016/j.etp.2011.07.004. View

2.
Rinne J . Nigral degeneration in Parkinson's disease. Mov Disord. 1993; 8 Suppl 1:S31-5. DOI: 10.1002/mds.870080507. View

3.
Huot P, Levesque M, Parent A . The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain. 2006; 130(Pt 1):222-32. DOI: 10.1093/brain/awl332. View

4.
Desmet K, Paz D, Corry J, Eells J, Wong-Riley M, Henry M . Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg. 2006; 24(2):121-8. DOI: 10.1089/pho.2006.24.121. View

5.
Bezard E, Dovero S, Bioulac B, Gross C . Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp Neurol. 1997; 148(1):288-92. DOI: 10.1006/exnr.1997.6648. View